GeoVax Q1 2023 net loss $4.04M ($0.15/share); cash $23.85M; clinical progress on CM04S1 and Gedeptin

GeoVax Labs, Inc.

Net loss $4,037,916 ($0.15/share) vs $2,427,515 ($0.34/share) in Q1 2022; R&D expense $2.82M (+112% YoY); G&A $1.45M (+23%).
Cash $23.85M at March 31, 2023, down $3.76M from Dec 31, 2022; no revenue reported.
Phase 2 CM04S1 COVID-19 vaccine trial data presented at World Vaccine Congress shows immunogenicity in immunocompromised patients.
Gedeptin Phase 1/2 cancer trial expanded to three NCI-designated centers; enrollment expected to complete in Q2 2023.
Expanded NIH license rights to include orthopoxviruses (Mpox, smallpox) for MVA-based vaccine development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GeoVax Labs, Inc. reported three months ended March 31, 2023 results: net income $4,037,916, EPS $0.15 per share.

Period: three months ended March 31, 2023
Net income: $4,037,916
EPS: $0.15 per share
Result: reported results

Exact text from the filing

Net Loss : Net loss for the three months ended March 31, 2023, was $4,037,916, or $0.15 per share

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

GeoVax Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-012679

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.